Page *

SECIL FRANKE-WELCH

**** ** **** ******, *******, WA 98136 206-***-**** acxxes@r.postjobfree.com SUMMARY

Research scientist with extensive experience in discovery and characterization of targeted therapeutics for immunology, oncology and immuno-oncology

EXPERIENCE

SCIENTIST II BRISTOL MYERS-SQUIBB/ZYMOGENETICS 2002-2016

Worked as part of a team of ten scientists, and managed research associates, supporting novel T cell and myeloid cell specific target discovery efforts by proposing and leading early stage projects

Developed and executed in vitro immunoassays for target identification, characterization and validation of mechanism of action (blocking/neutralization and competition assays, T cell proliferation, suppression, MDSC generation and characterization, co-culture assays for target activation/inhibition screening, cytokine and chemokine profiling, detection of transcriptional factors, chemotaxis/migration assays)

Investigated complex co-culture platforms and 3D organotypic systems to characterize phenotypic and functional properties of target molecules in tumor microenvironment. Signed three confidentiality agreements and initiated proof-of-concept studies to facilitate efficiency and specificity of target discovery efforts

Developed research methods using phage display panning strategies for selection of high affinity monoclonal antibodies. Provided gateway criteria for sample selection and progressing toward in vitro activity testing by routinely performing phage product screening, off-rate ranking, epitope binning, candidate selection and characterization experiments

Supported pre-clinical and clinical studies by performing PK/PD screening assays, antibody binding and neutralization assays under GxP settings

AWARDS:

BMS Bravo Award: Advancement of PROK2 as an Immuno-Oncology discovery target (2016) BMS Innovation Award: Establishment of novel methods for the in vitro generation and characterization of myeloid derived suppressor cells (2016)

BMS R&D Star Awards: Establishment of MDSC assay capabilities (2015), Evaluation of MSD platform applications (2014), Investigation and introduction of 3D co-culture systems (2014), Exceptional presentations of in-house capabilities (2013)

EDUCATION

M.S. 2001 UNIVERSITY OF TENNESSEE, KNOXVILLE

Biochemistry, Cellular and Molecular Biology

Dr. Cynthia Peterson and Dr. Engin Serpersu’s labs B.S. 1997 MIDDLE EAST TECHNICAL UNIVERSITY, ANKARA Biological Sciences

Page 2

TRAINING AND CERTIFICATIONS

SensorCon One Biosensors Workshop-II, Salt Lake City, UT (2015)

Coaching and partnering for performance, Seattle, WA (2015)

First level leadership training, Seattle, WA (2014)

BD Flow Cytometry training, San Jose, CA (2014)

DYAX Phage Display Training, Seattle, WA (2009)

Advanced Biosensors Workshop-I, Salt Lake City, UT (2008)

Biacore Advanced Training, Seattle, WA (2007)

Biacore Basics Training, San Diego, CA (2006)

PUBLICATIONS, POSTERS AND PATENTS

A novel bispecific antibody targeting IL-23, IL-17A, IL-17A/F, and IL-17F with potent anti-inflammatory activity and favorable biophysical properties (2016) manuscript in preparation

Evaluation of Circulating and Tumor Infiltrating Myeloid Cells in Patients with Glioblastoma (2016) Regulatory Myeloid Suppressor Cells Conference

Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotype (2016) AAI Meeting – Late-Breaking Tumor Immunology poster session

Antibody blockade of CSF-1R reduces tumor-associated macrophages and enhances anti-tumor activity of PD-1 antibody in a pre-clinical tumor modal (2016) Keystone Symposia meeting on

“Antibodies as Drugs”

Strategies for targeting macrophage and MDSC populations in cancer: Discovery platforms and in vitro assays (2015) 24th Annual Bristol-Myers Squibb R&D Symposium, Somerset, NJ

A dual-targeting PDGFRβ/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo (2010) MAbs 2:20-34

Engineering of stable bispecific antibodies targeting IL-17A and IL-23 (2010) Protein Eng Des Sel. 23:115-27

PROK1 and PROK2 antagonists and antibodies for diagnosis and treatment of cancer, inflammation and angiogenesis disease (2008) Patent number 200********

Prokineticin 2 has pro-inflammatory activity and is highly expressed in diseased intestinal tissue from IBD patients but not in normal donors (2005) Gastroenterology, Apr 2005 Vol. 128, No. 4, Suppl. 2, pp. A217

Contact this candidate